Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

Core Viewpoint - Investors are expected to focus on the sales performance of Immunocore Holdings plc's sole marketed drug, Kimmtrak, during the upcoming fourth-quarter 2024 results, with a consensus estimate of $83.5 million in revenue and a loss of 40 cents per share [1]. Group 1: Sales Performance and Market Presence - Kimmtrak is approved in 38 countries and has been launched in 21 countries, serving as the standard of care for metastatic uveal melanoma (mUM) in most markets where it is available [3]. - Revenue for the upcoming quarter is anticipated to be driven by increased sales of Kimmtrak in the U.S. and other markets due to strong demand [4]. - The company aims to expand its reach to more mUM patients globally by 2025 through additional launches and increased community penetration [5]. Group 2: Pipeline and Development - Immunocore is developing brenetafusp in combination with Bristol Myers' Opdivo for treating first-line advanced cutaneous melanoma, with studies also targeting other cancer indications [5]. - The company has a robust pipeline with nine active clinical and pre-clinical programs across oncology, infectious diseases, and autoimmune diseases, with updates expected in the upcoming earnings call [8]. Group 3: Earnings Performance and Predictions - Immunocore has a mixed history of earnings surprises, having beaten earnings estimates in two of the last four quarters, with an average surprise of 25.57% [9]. - The company's Earnings ESP is +20.57%, indicating a potential earnings beat, with the most accurate estimate at a loss of 32 cents compared to the consensus estimate of a loss of 40 cents [11].